This study successfully predicted six potential core targets, including mitogen-activated protein kinase 8 (MAPK8), catenin beta-1 (CTNNB1), nuclear factor NF-kappa-B p105 subunit (NFKB1), epidermal growth factor receptor (EGFR), apoptosis regulator Bcl-2 (BCL2), and nuclear factor erythroid 2-related factor 2 (NFE2L2), and six effective components, including lignan, β-carotene, β-sitosterol, hederagenin, berberine, and baicalein, involved in the therapeutic strategy for AD using LJF. The gene discussed is MAPK8; the disease is Alzheimer disease.